The firm said many testing locations could benefit from the system’s performance, including medical centers and places frequented by the public.
The test measures multiple host-response proteins in serum to determine whether a COVID-19 patient is likely to experience severe outcomes.
The EUAs for Gravity and Curative's tests were revoked because they are no longer used by the companies, while BioFire's test now has FDA clearance.
The firms have agreed to transition the business to Beckman, with Quidel receiving annual payments until 2029.
The test is designed to detect total antibodies against SARS-CoV-2 in serum and plasma to help identify people with an adaptive immune response to the virus.
The laboratory has specialized testing services for gastrointestinal pathology, dermatology, oncology, urology, and women's health.
The BioLegend deal, the largest in PerkinElmer's history, is expected to provide $.30 of adjusted earnings per share in the first full year following the close of the deal.
Gamidor, a provider of products and services to clinical labs, hospitals, and academic research institutions in Israel, will distribute PixCell's hematology analyzer.
Last week, readers were most interested in Chembio reporting an increase in its preliminary Q2 revenues while it faced an SEC investigation.